Perimenopausal and postmenopausal hormone replacement therapy: Part 1. An update of the literature on benefits and risks

Journal of Nurse-Midwifery

Volumn 41, Issue 1, 1996, Pages 3-28

  Lichtman, Ronnie ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CLIMACTERIUM; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; MENOPAUSE; MIDDLE AGED; NEOPLASM; PHYSIOLOGY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CLIMACTERIC; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; NEOPLASMS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; RISK FACTORS;

EID: 0029683157     PISSN: 00912182     EISSN: None     Source Type: Journal    
DOI: 10.1016/0091-2182(95)00082-8     Document Type: Article

References (269)

1. U.S. Department of Health and Human Services. Vital statistics of the United States. 1989. Volume II: Mortality, Part A. Hyatts uille, MD: U.S. Government Printing Office. DHHS Pub. No. (PHS) 93-1101, 1993
2. McKinby SM, Brambilla DJ. Posner JG. The normal menopause transition. Maturitas 1992,14:103-15.
3. Barrett-Connor I:. Epidemiology and the menopause: a global overview Int J Fertil Menopausal Stud 1993;1:6-14.
4. Moon TE Estrogens and disease prevention (editorial). Arch Intern Med 1991;151:17-8.
5. Lichtman R. Perimenopausal hormone replacement therapy review of the literature. J Nurse Midwifery 1991;36:30-48.
6. World Health Organization. Research on the menopause WHO Tech. Rep. Ser No. 670 Geneva. WHO, 1981
7. Harper DC: Perfanenopause and aging. In: Lichtman R, Papera S (eds). Gynecotogy: well-woman care. Norwalk. CT Apptelon & Lange. 1990
8. Schwarte J. Freeman R, Frishman W. Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women J. Clin Pharmacol 1995;35:314-29.
9. Kennedy DL. Baum C, Forbes MB. Noncontraceptive estrogens and progestins: use patterns over time. Obstet Gynacol 1985: 65:441-6.
10. Wysowski DK. Golden L. Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States. 1982-1992. Obstet Gynecol 1995;85:6-10
11. Mischell DR Comment. Focus Opin Obstet Gynecol 1995;1. 210
12. Schnatt N. Gogate J, Rothert M, et al. Capturing and clustering women's judgment policies: the case of hormonal therapy fur menopause. J Gerontol 1991;46:92-101.
13. Roberts J, Blake, J. Baumann A. Chambers L. Women and decision melting: hormone replacement therapy. Womens Health Issues 1995:5:40.
14. Hunter MS, Ljao KL. Intentions to use hormone replacement therapy in a community sample of 45-year old women Maturitas 1994;20:13-23.
15. Utian WH Schiff I. NAMS-Gattup survey on women's knowledge, information sources, and attitudes to menopause and hormone replacement therapy. Menopause 1994;1:39-48.
16. Abraham S. Perz J. Ctarkson R, Liewellyn-Jones D. Australian admen's perceptions of hormone replacpment therapy over 10 years Maturitas 1995;21:91-5.
17. Caulev JA, Cummings MD. Black DM, Mascidi SR, Scelcy DG. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol 1990 163:1438-44.
18. Egeland GM, Kuller LH, Matthews KA, Kelsey SF, Cauley J, Guzick D. Premenopausal determinants of mcnopausal estrcjen use. Prev Med 1991:20:343-9.
19. Hemminki E. Malin M. Topo P. Selection to postmenopausal therapy by women's characteristics. J Clin Epidemiol 1993;46:211-9.
20. Hammar M. Berg G, Fahraeus L, Larsson-Cohn U. Climac teric symptoms in an unselected sample of Swedish women. Maturitas 1984;6:345-50.
21. Avis NE, Brambilla D, McKinlay SM, Vass K. A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women's Health Study. Ann Epidemiol 1994;4:214-20,
22. Stewart DE. Boydell KM. Psychologic distress during menopause, associations across the reproductive life cycle Int J Psychiatry Med 1993;23:157-62.
23. Koster A. Davldsen M. Climacteric complaints and their relation to menopausal development: a retiospective analysis. Maturitas 1993:17:155-66.
24. Kuller LH, Meilahn EN, Cauley JA, Gutai JP, Matthews KA. Epidemiologie studies of menopause: changes in risk factors and disease Exp Gerontol 1994;29:495-509
25. Miles TP. Malik KC. Menopause and African-American women: clinical and research issues Exp Gerontol 1994:29:511-8.
26. Standing TS. Glazer G Attitudes of low-income dinic patients toward menopause. Health Care Women Int 1992;13:271-80.
27. Morse CA, Smith A, Dennerstein L. Green A. Hopper J. Burger H. The treatment-seeking woman al menopause. Maturitas 1994;18:161-73.
28. Liao K. Hunter MS. White P. Beliefs about menopause of general praclilioncrs and mid-aged women. Fam Pract 1994;11:408-12
29. Hunter M The South East England longitudinal study of the climacteric and postmenopausc. Maturitas 1992:14:117-26
30. Avis ME, McKinlay SM A longitudinal analysis of women's attitudes toward the menopause: results from the Massachusetts Women's Health Study Maturitas 1991;13:65-79.
31. Matthews KA. Myths and realities of the menopause. Psychosom Med 1992;54:1-9
32. Matthews KA, Kuller LH Wing RR. Meilahn EN Biobehavioral aspects of menopause: lessons from the healthy women study Exp Getontol 1994;29:337-42.
33. Beyene Y. Cultural significance and physiological manifestations of menopause; a biocultural analysis. Cult Med Psychiatry 1986: 10:47-71
34. Martin MC. Block JE. Sanchez SD. Arnaud CD. Beyene Y. Menopause without symptoms, the endocrinology of menopause among rural Mayan Indians. Am J Obstet Gynecol 1993:168:1839-43
35. Dietsch E. Is it pathological to be female? Oestrogen deficiency symptoms i:. 347 women aged 15 to 69 years. Aust J Adv Nurs 1994,12:8-13.
36. Holtt A, Mikkelsen A. The menopausal syndrome a lactor analytic replication. Maturitas 1991:13:193-203.
37. Garton M, Reid D, Rennie E. The climacteric, osteoporosis and hormone replacement views of women aged 45-49. Maturitas 1995;21:7-15
38. Collins A. Landgren BM. Reproductive health, use of estrogen and experwnce of symptoms in penmenopausal women, a populalion-based study. Maturitas 1994;20:101-111.
39. Avis NE, McKinlay SM. The Massachusetts Women's Health Study: an epidemidogic investigation of the menopause. J Am Med Worn Assoc 1995;50:45-9,
40. Hole A. Influence of natural menopause on health complaints: a prospective study of healthy Norwegian women Maturitas 1992:14: 157-60.
41. Kaufert PA. A health and social profile of the menopausal woman. Exp Gerontol 1994:29:343-50.
42. Ginsburg ES. Hot flashes: physiology, hormonal therapy, and alternative thrapies. Obstet Gynecol Clin North Am 1994;21:381-90.
43. Sherwrn BB. Gelfand MM. Effects of parenteral administration of estrogon and androgen on plasma hormone levels and hot fiushes in the surgical menopause. Am J Obstet Gynccol 1984;148:552-7.
44. Dennerstein L. Burrows GO, Hyman G, et al Menopausal hot flushes: a double-blind comparison of placebo. ethinyl oestradiol and norgestrel, Bt J Obstet Gynaecol 1978:85:852-6
45. Mattson LA, Samsioe G. Estrogen-progesiogen replacement in climacteric women, particularly regards a new type of continuous regimen. Acta Obstet Gynecol Scand 1985:130:53-8.
46. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urnary tract infections N Engl J Med 1993:329:753-6.
47. Heimer G, Englund DE. Effects of vaginally-administered oestnol on post-menopausal urogenital disorders: a cytohormonal study Maturilas 1992;14:171-9.
48. Nilsson K. Heimer G. Low-dose oestradiol in the trearument of urogenital oestrogen deficiency: a pharmacokinetic and pharmacodynamic srudy. Maturitas 1992;15:121-7.
49. Smitli P, Heimer G, Lindskog M. Ulmaen U. Oestradiolreleasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas 1993;16:145-54.
50. Reters H, Drogendijh AC, Valkenburg HA. Riphagen F. The menopause, urinary incontinence and other symptoms of the genitourinary tract. Maturitas 1992:15:101-11.
51. Elia G, Bergman A. Estrogen effects on the urethra: beneficial effects in women with genuine stress incontinence Obstet Gynecol Surv 1993;48:509-17.
52. Fantl JA. Cardwoz L. McClish DK. The Hormones and Urogenital Therapy Committee. Estrogen therapy in the management of urinary incottrience in postmtnopausal women a meta-analysis First report of thr hormones end urogenital therapy committee. Obstet Gymcol 1994;83:12-8
53. Marsh TD. Estrogens for treating urinary inrontinence in women. Am Pharm 1993;NS33:47-8, 90
54. Fand JA. The lower urinary tract in women: effect of aging and menopause or continenice. Exp Gerontol 1994;23:1417-22
55. Cardoro LD, Kdleher CJ Sechormones. themonopause and urinary problems Gynecolog Endocrinol 1995:9:75-84.
56. Sultona CJ. Walters MD. Estrogen and urinary incontinence in women. Maturitas 1994;20:129-38
57. Sarret PM. Sexuality and menopause. Obstet Gynecol 1990, 75:26S-35S
58. Sarrel PM, Whitehead MI. Sex and menopause: defining the Issues. Maturitas 1985;7:217-24
59. Dennerstein L. Smith AM. Morse CA. Burger HG Sexuality and the menopause. J Psychosom Obstet Gynaecol 1994;15:59-66
60. Kostet A. Garde K. Sexual desire and menopausal develop-ment. A prospective study of Danish women born in 1936 Maturitas 1993:16:49-60
61. Frock J, Money J Sexuality and menopause. Psychother Psy chosom 1992:57:29-33
62. Hawton K, Gath D. Day A. Sexual function in a community sample of middle-aged women with partners: effects of age. marital, socioeconomic, psychiatric, gynecologicol, and menopausal factors Arch Sex Behav 1994:23:375-95.
63. Walling M, Andersen BL. Johnson SR. Hormonal replace-ment therapy for postmenopausal women: a review of sexual out comes and related gynecologic effects. Arch Sex Behav 19:119-37.
64. Paterson MEL. A randomized. double-Wind cross-over study into the effect of sequential mestranol and norethisterone in climacteric symptoms and biochemical parameters. Maturitas 1982:4:83-94.
65. Sherwin BB, Gelfand MM. The role of androgen in the maintanance of sexual functioning in cophorectomized women. Psychosom Med 1987:48:397-409.
66. Sherwin BB, Gelfand MM, Brender W Androgen enhances sexual motivation in females: A prospective crossover study of sex stenid administration in the surgical menopause. Psychosom Med 1985:47:339-51.
67. Burger HG, Halles J. Menelaus M. Nelson J. Hudson B. Bal azs N. The management of persistent menopausal symptoms with oestriol-teslosterone implants: clinical, lipid, and hormonal results. Maturitas 1984:6:351-8.
68. Cardera L, Gibb DMF, Tuck SM. Tom MH, Studd JWW, Cooper DJ. The effects of subcutaneous hormone implants during the climacteric. Maturitas 1984:5:177-84
69. Ballinger CB. Psychiatric aspects of the menopause. Br J Psychiatry 1990:156:773-87
70. Wilbur J. Holn K, Dan A. The relationship of energy expenditure to physical and psychologic symptoms in women at midlife. Nurs Outlcots 1992:40:269-76
71. Wiklund I, Korlberg J, Mattssou LA. Quality of life of post-menopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controjled study. Am J Obstet Gynecol 1993; 168:824-30.
72. Daty E, Gray A, Barlow O, McPherson K, Rochc M, Vessey M. Measuring the Impact of menopausal symptoms on quality of hie. BMJ 1993;307:836-40.
73. Wiklund I Hobt J. Karlbert; J, et al. A new methodological approach to the evaluation of quality or life In postmenopausal women. Maturitas 1992;14:211-24.
74. Wiklund I. Berg G. Hammar M. Karlberg J, Lindgren R, Sandln K. Long term effect of transdermal hormonal therapy on aspects of quabty of life in postrnenopdusal women. Maturitas 1992;14:225-36.
75. Karlberg J. Matuson LA. Wikhjnd I, A quality of life perspective on who benefits from estradiol replacemerrf therapy. Acta Obstet Gynecol Scand 1995;74:367-72.
76. Maoz B. Shlber A, Lazer S, Kopemik G. The prevalence of psychological distrew among postrnenopausal women attending a menopausal clinic and the effect of hormone replacement therapy on then mental slow Menopause 1994,1:187-41
77. Siddle NC. Fraser D. Whitehead MI, et al. Endometrial. physical and psychological eifecls of postmenopausal oeitroger therapy with added dydrogesterone Br J Obstet Gynatcol 1090.97:1101-7
78. Pansini F. Albertazd P. Bonaccorsi G. et al The moenopausal transition: a dynamic approach to the pathogenesis of neurovegetative complaints. Eur J Obstet Gynecol Reprod Blot 1994:57:103-9
79. Dilkoff EC. Crary WO. Cristo M. Lobo R. Estrogen improves psychological function in asympjomatic postmeriopausai women. Obstet Gynecol 1991:78.991-5.
80. Palmkas LA, Barred-Connor E. Estrogen use and depressive symptoms in postmenopausal women. Obstet Gynecol 1992.80: 3()-6.
81. O'Connor VM. Del Mar CB, Sheehan M. Siskind V. Fox-Yomug S. Crang C. Do psycho-social factors contribute more to symptom reporting by middle-aged woman than hormonal status? Maturitas 1995.20:63-9.
82. Zachariascn RD. Oral manifestations ol menopause. Compendium 1993:14.1584. 1586-91.
83. Pisdntry S. Rafaely B. Polishuk WZ. The effect cf steroid hormones on buccal mucoso of menapausal women. Oral Surg Oral Med Oral Pathol 1975,40:346-53
84. Volpe A. Lucenti V. Forabosco A, et al Oral discomfort and hormone replacement therapy in the post-menopause. Maturitas 1990:13:1-5.
85. Casrelo-Branco C. Pons F, Gratacos E. Fortuny A, Vanrell JA, Gonzalez-Merlo J. Relationship between skin collagen and bone changes during aging. Maturitas 1994:18:199-206.
86. Jaliman D. Menopause and skin. Menopause Manage 1995: 4:34-8.
87. Fmster V. Grady D. Mike R. et al. Facial wrinkling in men and women, by smoking status. Am J Pub Health 1995;85:78-82.
88. Reus WF. Robson MC. Zacher L, et al. Acute effects of tobacco smoking on blood flow in the cutaneous micro-circulation. Br J Plast Surg 1984;37:213-5.
89. Richardson D Effects of tobacco smoke inhalation on capillary blood now in human skin. Arch Environ Health 1987;42:19-25
90. Sawas M, Bishop J, Laurent G. Watson N, Studd J. Type III collagen content in the skin of posln-.enopausal women receiving oesrradiol and testosterone implants. Br J Obstet Gynaecoi 1993;100 154-6
91. Pierard GE. Letawe C, Dowlate A. Pierard-I anchimont C. Eifect of hormone replacement therapy for menopause on the mechanical properties of skin. J Am Geriatr Soc 1995:43:662-5.
92. Maheux R, Naud F. Rtoux M, et al. A randomized, double-blind. placebo-controlled study on the effect of conjugated eslrogens on skin thickncss. Am J Obstet Gvnecul 1994;170:642-9.
93. Bauer DC, Grady D. Pressman A, the Study of Osteoporotic Fractures Research Group. Skin thickness, estrogen use, and bone mass in older women. Menopause 1994:1:131-6.
94. Creidl P, Faivre B, Agache P, Richard E. Haudiquet V, Sauvanet JP. Effect of a conjugated oestrogen (Premarin) cream on aging facial skin: a comparative study with a placebo cream. Maturitas 1994: 19:211-23
95. Schmidt JB. Binder M. Machiner W. Kaintz C. Gitsch G. Bicglmayer C. Treatment of skin ageing symptoms In perir enopausal females with estrogen compounds: a pilot study. Matunias 1994:20-25-30
96. Specter TM, Brennan P. Harris P. Studd JWW, Silman AJ Does estrogen replacement therapy protect against rheumatoid arthritis? J Rheumatd 1991:18:1473-6.
97. Conet B, Flipo RM, Duquesnoy B. Dekambre B. Bone tissue in rheumatoid arthritis (2): pathophysiologic data, pathologic findings, and therapeutic implications. Rev Rhum Ed Eng 1995;62:205-11.
98. Van Vollenhoven RF, McGuive JL. Estrogen, progesterone, and testosterone: can they be used to treat autoimmune disease? Cleve Clin J Med 1994:61:276-84.
99. Hemandez Avila M, Lang MH. Willett WC. et al. Exogenous Sex hormons and the risk of rheumatoid arthritis Arthritis Rheum 1990:33:947-53.
100. Koepsdl TD. Dugowson CE. Netson JL. Voigt LF. Daling JR Non-contracepthw hormones and the risk of rheumatoid arthritis in meropausal women. Int J Epidemlol 1994,23:1248-55
101. MacDonald AG. Murphy EA. Capell HA. Bankowska UZ. Ralston SH. Effects of hormone replacement therapy in rheumatoid arthritis: a double bend placebo-controlled study Ann Rheum Dis 1994; 53:54-7
102. Gibbs RB. Estrogcn and nerve growth factor-related systems in brain: effects on basal forebrain cholinergic neurons and implications for teaming and memory processes and aging. Ann NY Arad Sci 1994:743:197-9.
103. Sherwin BB. Estrogenic effects on memory in women. Ann NY Acad Sei 1994;743,213-30.
104. Burrett-Connor E, Kritz-Silwrstein D Estrogen replacement therapy and cognitive function in older women JAMA 1993.269: 2637-41.
105. Shenwri BB Estrogen and/or anclrogen replacement therapy and cognitivi functioning in surgically menopausel women Psycho neuroendocrinuiogy 1988.10-325-35.
106. Sheruin BB. Phillips S. Estrogcn and cognitive functioning in surgically monopolisai women Ann NY Acad Sei 1990:592:474-5.
107. Phillips SM, Sherwin BB. Effects of eslrogcn on memory func lion in surgically menopausal women. Psychoneuroendccrinology 1992;17:485-95,
108. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal womnn. Obstet Gynecol 1994:83:979-83.
109. Robinson D. Friedman L. Marcus R. Tinklenberq J. Yesavage J. Estrogen replacemenl therapy and memory in older women. J Am Geriatr Soc 1994:42:919-22.
110. Brenner D. Kukull M. Siergachis A. et al Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidtmiol 1994:140; 262-7
111. Pagantni-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer'sdisease in women Am J Epkfemiol 1994:140:256-61.
112. Henderson VW. Paganini-Hill A. Emanuel CK, Dunn ME. Buckwalter JG. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control si-hjscts. Arch Neurol 1994:51:896-900.
113. Fillit H. Fctrogens in the palhogencsis and treatment of Alzheimer's diseaw in postmenopausal women. Ann NY Acad Sei 1994; 743:233-8.
114. Fillit H. Weinreu H. Choisi I, et al. Observations in a preliminary open trial of estradiol therapy for serntle dementia-Alzheimer s type. Psychoneuroendocrinology 1986:41:337-45.
115. Honjo H, Tanaka K. Kashiwag T. et al. Senile dementia-Alzhtimer's type and estrogen. Horm Metab Res 1995,27:204-7.
116. Ohkura T. Isse K. Akazawa K. Hamamoto M, Yaoi Y, Hagino N. Low-dose astrogen replacement therapy for Alzheimer disease in women. Menopause 1994;1:125-30.
117. Nachtigall LJ, Nachtigall RH. Nachtigall RO, et al. Estrogen replacement therapy 1: a 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol 1979:53:277-81.
118. Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortlccl and trabecular bone: comparison with estrogen. Am J Med 1991;90:171-8.
119. Watts MB, Notelowtz M. Timmons MC, Addison WA, Wiita B, Howney LJ. Comparison of oral estrogens and estrogens plus andro gen on bone mineral density, menopausal symptoms, and lipid lipoprotein profiles in surgical menopause. Obstet Gynecol 1995:85: 529-37.
120. Cundy T. Evans M. Helen R. Wattle D. Ames R. Reid IR. Bone density in women receiving depol mcjroxyprogesterone acstate for contraception. BMJ 1991:303.13-16.
121. Hillard TC, Whitcroft SJ, Marsh MS, et al. Long-term effects of transdennal and oral hormone replacement therapy on postmenordtnai bone luss. Osteoporos int 1994;4:340-8
122. Palucios S. Menendcz C. Jurado AR. Vargai JC Effects of percutaneous oesitradiol versus ural estrogcm on bone density Maturilas 1995,20:209-13
123. Stevenson JC Cusl MP. Gangar KF. Hillard TC. Lees IS. Whltehead Ml. Effects ol transdemtal versus oral hermone replace ment therapy on bone density in spine and proximo femur in postmenopausal women. Lancet 1990:335:265-9.
124. Bellarrf JE, McKeown BC. Graham HM. Zinkgral SA. The effect of high level physical activity (85 METs or greater) and estroger. replacement therapy upon bone mass in poslmenopausal females, aged 50-63 years Int J Sports Mecl 1990;11:208-14.
125. Noteloviti M. Martin D, Tesar P.. at al Eitrogen therapy and variable-resistance weight training increase bone mineral in surgically menopausal women J Bone Miner Res 1901.6.583-90.
126. Prince RL, Smith M. Dick IM. et al. Prevention of postmenopausal osteopoictois. a comparative study of exercise, calcium supplementation, and hormone replacement therapy N Engl J Med 1991; 325:1189-95
127. Meschia M. Brincat M. Barbacini P. Crossignani PC, Albisetli W. A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early poitmenopausel women. Calcii Tissue In. 1993:53:17-20
128. Aloia JF. Vaswani A, Yeh JK, Ross PL. Raster E, Dilmanian KA. Calcium suppletmcnlation wilh and without hormone replacement therapy to prevent poslmenopausal bone loss. Ann Intetn Med 1994: 120:97-103.
129. Hasting C. Charles P, Jensen FT. Mosekilde L A comparison of the effects of oestrogen/progestogen. high-dose oral calcium, intermittent cyclir etidronate and an ADFR regime or. calcium kinetics and bone mass in postmenopautai women with spinal oiteoporosis. Osteoporos Int 1994:4.191-203
130. Naessen T, Persson I. Thor L, Mallmin H. Ljunghalt S. Bergstrom R. Maintained bone density at advanced ages after long term treatment wilh low dose oestradioi implant: Br J Obslet Gynaeeol 1993:100454-9.
131. Naessen T. Petbson I. Adami HO. Bergsirom R, Bergkvist L, Hormone replacement therapy and the risk for first hip fracture: a prospective, population-based cohort study. Ann Intern Mad 1990; 113:95-103.
132. Cauley JA. Seelcy DG. Ensrud K. et al Estrogen repiacement therapy and fractures in older women Ann Intem Med 1995,122:9-16.
133. Maxim P. Ertrnger B. Spitalny GM. Fracture protection provided by long-term estrogen treatment. Osteoporos Inl 1995:5:23-9.
134. Shou-qing L, Qin sheng G. Fu-ying Y. Dan-dan F, Hui-lan W. The effect of taw-dose estrogen and progeslogen on menopausal symptoms and urinary excretion of calcium. Chm Med J 1990:103: 652-7.
135. Hall V. Petirti DB, Ettinger B. Quesenbeny C. Does estrogen replacement therapy prevent heignt lass? Menopause 1994:1:3-9.
136. Pun KK, Wong FH, Loh T. Rapid postmenopausal loss of total body and regional bone mass in normal southern Chinese females in Hong Kong. Osteoporos Int 1991.1:87-94
137. Soroko SB, Banett-Conrtor E. Edelstein SL, Kriu-Sihwrsiein D. Family history of osteoporosts and bone mineral density at the axial skeleton: the Rancho Bemando Study. J Bone Miner Res 1994:9: 761-9
138. la Vecchia C. Negri E. Lcvi F. Baron JA. Cigarette smoking, body mass and other risk factors for fraclures of the hip In women. Int J Epidemiol 1991;20:671-7.
139. Marcus R. Greendale G. Blunt BA, et al Correlates of bone mineral density in the postmenopausal estrogen/progestin intetwnlions trial. J Bone Miner Res 1994:9:1467-76.
140. Sowers MR. Clark MK. Jannausch ML. Wallace RB. Body sue. estrogen use and thiazide diuretic use affect 5-year radial bune loss in postmenopausal women Osteoporos Int 1993:3:314-21.
141. Holbrook TL. Barrctt-Connor F. The association of lifetime weight and weight control patterns with bone mineral density in an adun community, bone Miner 1993:20:141-9.
142. Ktau O. S-nborn CF, Nichota OL. Bonrrtrk SU Alford 86 Anocirtoru of body fat disrterution. circulating sex hormones, and bone faulty In postmenopausal women J Chn Enducriro Metab 1995;80:1591.
143. Krtz-Sttirmttain D, Bamett-Connor E. Early menopause, num bar of reproductive years, and bornet mineral deniily In postmenopiusal woman. Am J Pub Health 1993.83.983-8.
144. Gambaectani M. Spinetti A, Taponeco F. ut al Bone loss in pertmrnopousal wonwn. a longitudinal study. Motuittas 1994,18: 191-7
145. Tuppuraipen M. Kroger H. Saarikoski S Honkanen R. Alhava E. The effect of gynecological risk factors on hanibar and femoral bons mineral density In peri- and postmenopausal women. Maturiias 1995, 21:137-45.
146. Kritz-Silverstein D. Barren-Connor E. Hollenbach KA. Preg nancy and lactation as determinants of bone minerai density in post mcnopausal woman. Am J Epidemid 1992;136.1052-9.
147. Sawn M, Wallace RB. Lernke JH Correlates of forearm bone mass among women during maximal bone mbwralizalion Prev Mad 1985;14:585-96
148. Sowers MFR, Clark MK. Mollis B, et al. Radial bone mineral density in pre- and perirnenopausal women a prospective study of rates and risk factors for loss. J Bone Miner Res 1992:7:647-57.
149. Hollenbaeh KA, Barrett-Connor E. Edelstein SL. Holbrook T Cigarette smoking and bone mineral density in older men and women Am J Pub Heslth 1993:83:1265-70
150. Hansen MA. Overgaard K, Rfii BJ, Oimtiansen C. Potential risk factors for development of poslmenopeusal osteoporosls exarninedovera 12-year period. Osteoporwls Int 1991:1:95-102.
151. Hodges SJ. Pilklnglon MJ. Stamp TCB, et al. Depressed levels of circulating menaquinones in patients with osteoporotic fractures of the spine and femoral neck Bone 1991:12:387-9.
152. Barrett-Connor E. Change JC, Edelstein SL. Coffee associated osteoporosis offset by daily milk consumption. JAMA 1994;271:280-3.
153. Graendak GA, Barrett-Connor E. Edelstein S. Ingles S. Halte R. Lietary sodium and bone mineral density: results of a 16-year follow-jup study. J Am Geriatr Soc 1994;42:1050-5.
154. Sowers MR, Gahiska DA. Epidemiology of bone mass in premenopausal women. Epidemtol Rev 1993;15:374-98.
155. Kitng AWC, Pun KK. Bone mineral density in premenopausal women receiving long-terrn physiological doses of levothyroxine. JAMA 1991;265:2688-91
156. Cundy T, Evans M, Roberts H, Watlie D. Aines R, Reid IR. Bone density at women receiving depot medroxyprogesterone acetate for contraception BMJ 1991;303:13-6
157. Soroko 5, Hotnuok TL. Edelstein S. Barrett-Connor E. Life-time milk consumption and bone mineral density In older women Am J Pub Health 1994;84:1319-22
158. Andon MB, Smith KT, Bracker M, Sartoris D, Sattman P. Strauie L. Spinal bont density and calcium Intake in healthy post-menopausol women. Am J Clin Nutr 1991;54:927-9.
159. Johnston CC, Miñer JZ, Stenenda CW. et al. Calcium supplementation and bicneases m bone mineral density ir. children. N Engl J Med 1992:327:82-7.
160. Lloyd T, Andon MB, Rollings N, et al. Calcium supplementation and bone mineral density in adolescent girls. JAMA 1993.270: 841-4.
161. Grove KA, Londeree BR. Bone density hi postmenopausal women: high Impact vs. low Impact exercise. Med Sei Sports Exere 1992;24:1190-4,
162. Krttz-Silversteln D. Barrett-Connor E. Bone mineral density in postmenopausal women as determined by prior oral contraceptive use. Am J Pub Health 1993;83:100-2.
163. Perry W, Anderaon M. Mortimer C. Osteoporosh in a largely self-referred population: high prevalence but low medical priority: why? Miner Electrolyte Metab 1994;20;287-93,
164. Smidt GL Un SY, O'Duuyer KD, Blanpmd PR Tho effect of high-intensity trunk exercise on bone mineral density of postmenopausal woman. Spinc 1992;17:280-5.
165. Adaml S Optimising peak boop mass what are the therapeutic possibltiies? Osteoportos Int 1994:4:27-30
166. Dawson Hughes B. Harris SS. Krat EA. et al Vitamin D and bone loss in posntenopausal woman. Am J Clin Nutr 1995:61:1140-5
167. 3 and cakiuri to prevtent hip fractures in elderly women N Engl J Med 1992;327:1637-42
168. Danielson C Hip fractures and fluoribtion JAMA 1992: 263:746-8.
169. Kanis JA. Adami S. Bone loss in the elderly. Osteoporosis Int 1994.4:59-65
170. Stampfer MJ. Colditz GA. Eitrogon replacement therapy and coronary heart disease a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
171. Grddy D. Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postenenopausal woman. Ann Intem Med 1992;117:1016-41.
172. Vandenbroucke JP. How much of the catdioprotectivc effect of post -ponopausal estroqens ia real? Epidemiology 1995;6:207-8.
173. Posthuma WFM, Westendorp RGJ, Vandenbroucke JP. Cardioprotective effect of hormone replacement therapy in poslmenopausal women: is the evidence biased? BMJ 1994.303:1268-9.
174. Surgeon SR, Schairer C, Brinton LA. Peason T. Hoover RN. Ewdence of a healthy estrogen user survivor effect. Epidemiology 1995:6.227-31.
175. Petltti DB. Coronary heart distase and esirogen replacement therapy: can compliance bias explain the results of observational studies? Ann Epidemiol 1994;4:115-8.
176. Nachtigall LJ. Nachltqall RH. Nachtigall RD, et al. Estrogon replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979:54: 14-9.
177. Stampfer MJ. Willert WC. Cotditz GA. Rosner B. Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Ergl J Med 1985;313:1044-1049.
178. Stampfer MJ, Bechtel SD. Estrogen; what protection against heart disease? Conl Ob/Gyn 1992:13-20, 323-4, 29-30.
179. Lobo RA. Cardiovascular implioatiotis of estrogen replace-ment therapy. Obstet Gynecol 1990;75:18S-24S.
180. Davis CE, Pajak A, Rywik S. et al. Natural menopause and cardiovascular disease risk factors: the Poland US Collaborative Study on Cardiovascular Disease Epidemiology. Ann Epidemiol 1994:4: 445-8
181. Razay G, Heaton KW, Bohon CH. Coronaru heart disease risk factors in relation to the menopause. Quart J Med 1992,85:889-96
182. Knopp RH. Zhu X, Bonct B Effect of estrogens on lipoproteln metabolism and cardiovascular disease in women. Atherosclerosis 1994;110:S83-S91
183. Gorodeski GI. The effects of ERT/HRT on CVD. Menopause Manage 1995;4:10-2, 17.
184. Stevenson JC. The metabolic and cardiovascular consequences of HRT Br J Clin Pract 1995:49.87-90
185. Suflivan JM, Vander Zwaag R. Hughes JP. et al. Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med 1990;150:2557-62.
186. Brett KM, Madans JH, Luog-term survival after coronary heart disease: comparisons between men and women In a national sample. Ann Epidemiol 1995;5:25-32.
187. Ingamar P, Adaml HO. Reinhold B. Brith KU, Robert H. Survival in women receiving hormone replacement therapy: a recordlinkage study of a large population-based cohort. J Clin Epidemiol 1990:43:677-85.
188. Hunt K, Vessey M. McPherscn K Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990;97:1080-6.
189. Henderson BE, Paganini-Hill A, Ross RK. Decieased mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 151:75-8
190. Wolf PH, Madans JH. Finucane FF, Higgins M. Kleinman JC Reduction of cardivasculor disease related mortality among post-menopausal women who use hormones evidence from a national cohort Am J Obstet Gynecol 1991;164:489-94
191. Ettinger B Homone replacement therapy and coronary heart disease. Obstet Gynecol Clin North Am 1990;17:741-57
192. Rosenberg L. Palmer JR. Shapiro S. A case-control study of myocardial infarction in relation to use of estrogen supplements. Am J Epidemiol 1993;137:54-63
193. Avila MH, Walker AM. Jick H. Use of replacement estrogens and the risk of myocardial infarction. Epidemiol 1990;1:128-33.
194. Psary BM. Heckbert SR. Atkins D, et al. The risk of myoeandial infarction associated with the combined use of cstrogero and progestins in postmenopausal women Arch Intern Med 1994,154:1333-9
195. Stampfer MJ. Coldilz GA. Willett WC. et al Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses Health Study. N Engl J Med 1991:325:756-62
196. Finucane FF. Madam JH, Bush TL, Wolf PH. Kleinman JC. Decreased risk of stroke among poslmenopajsal hormone users: results from 4 national cohort. Arch Intern Med 1993:153:73-9.
197. Falkebom M, Persson I. Terent A, Adami HO. Lithell H. Bergstrom R. Hormone replacement therapy and the risk of stroke: followup of a population-based cohort in Sweden. Arch Intern Med 1993: 153.1201-9.
198. The Writing Group for the PEPI Trial. Effects of estrogen or eshogen/progeslin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Inter ventions (PEPI) Trial. JAMA 1995:273:199-208.
199. Samsioe G. Cardioprotection by estrogens: mechanisms of action: the lipids. Int J Fertil Menopwuwl Stud 1994;39:43-9
200. Mattsson LA, Samsioe G. von Schoultz B, Uuebranl M. Wiklund I. Transdermally administered oestradlol combined with oral me droxyprogesterone acetate: the effects on lipoprotein metabolism in Postmenopausal women, Br J Obstet Gynaecol 1993;100:450-3.
201. Crook D, Cust MP, Gangar KF, et al Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992;166:950-5
202. Wakh BW. Schiff I. Rosner B, Greenberg L, Ravnikar V. Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoprotcins N Engl J Med 1991;325:1196-204.
203. Walsh BW. LJ H. Sacks FM. Effects of postmenopausal hor rnone replacement with oral and transdermal cstrogen on high density lipoprotein metabolism. J Lipid Res 1994;35:2083-93.
204. Hong MK, Romm PA. Reagan K. Green CE. Rackley CE Effects of estrutjen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women Am J Cardiol 1992;69:176-8.
205. Mooijoni S. Dupont A. Labrie F. et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metab 1991;73:373-9
206. Bolaji II. Grimes H. Mortimer G. Talion DF. Fottrell PF. O'Dwyer FM. Low-dose progesterone therapy in oestrogenised post menopausal women: effects on plasma lipids, lipoproteins and liver function parameters. Eur J Obstet Gynecol Reprod Biol 1993:48: 61-8.
207. Christiansen C. Riis BJ Five years with continuous combined oestrogen/progestogcn therapy: effects on calcium metabolism. lipoproteins, and bleeding pattern. Br J Obstet Gynaecot 1990:97; 1087-92.
208. Kable WT. Gallagher JC. Nachtigall L, GoWgar D Lipid changes after homone replacement therapy for menopause J Reprod Med 1990:35:512-8.
209. Siddle NC, Jesinger DK Whitehead MI, Turner P. Lewis B. Prescott P. Effect on plasma lipids and lipoprotdns of postmenopdusal oestrogen therapy with added dydrogeslerone. Br J Obstet Gynaecol 1990:97:1093-100
210. Cano A, Femandes H. Serrano 5. Mahiques P. Effect of con-tinuous oestradiol-medoxyprogesletone administration on plasma lipids and lipoprotetris Maturitas. 1991:13:35-42
211. Haarho J. Hassager C. Jensen SB. Rüh BJ. Christiarocn C Serum lipids, lipoproteine, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19 nortestosterone derivatives or 17-hydroxyprogesterone derivatives Am J Med 1991;90:584-9
212. Tufekci M, Colak Z. Ozan H, Kirnya V, Aydmlar A. Effect of progestogens on estrogen induced hpoprolein changes Eur J Obstet Gynecol Reprod Biol 1993,49:169-74.
213. Miller VT. Muesing RA. LaRosa JC, Stoy DB. Phillips EA. Stiilman RJ. Effects of conjugated equine estrogen with and without three different progestogens on lipoproicins. high-density hpoprotem subfractions, and apolipoprotein A-l. Obstet Gynecol 1991:77:235-40.
214. Watts NB. Notdovitz M, Timmons MC. Addison WA, Wiita B. Downey LJ. Comparison of oral estrogens and estrogens plus andregen on bone mineral density, meriopausal symptoms, and lipid-lipourotein profiles in surgical menopause. Obstel Gynecoi 1995:85: 529-37.
215. Nabulsi AA. Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in pcstmenopausal women: the Atherosclerosis Risk in Communities Study Investtgdtors. N Engl J Med 1993:328:1069-75.
216. Hickok LR, Toomey C, Speroff L. A comparison of esterified estiogens with and without methyttestosterone: efiects on endometrial histology and serum lipoprotcins in postmenopausal women. Obstet Gynecol 1993:82:919-21.
217. Tadmor OP. Kteinman Y. GoHstein R, Diamant YZ. The effect of desogestrel for hormone replacement therapy cm the blood lipid profiles of postmenopausal women. Int J Gynatol Obstet 1992:39: 105-10
218. Marsh MS, Crook D, Whitcroft SIJ. Worthington M, Whitehead Ml, Stevenson JC Effect of continuous combined estrogen and dcsogestrcl hormone replacement therapy on serum lipids and lipoproteins Obstet Gynccol 1994:83:19-23.
219. Gebara OC, Mittlernan MA. Sutherland P. et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingharo Offspnng Study. Circulation 1995;91:1952-8
220. Lee AJ, Lowc GD. Smith WC. Tunstall-Pedoe H. Plasma fibrinogen in women: relationships with oral contraception, the menopause and hormone replacement therapy. Br J Haematol 1993:83: 616-21.
221. Bar J. Tepper R. Fuchs J, Pardo Y, Golderger S, Ouadia J. The effed of estrogen replacement therapy or platelet aggregation and adenosine triphosphate release in postmenopausaJ women. Obstet Gynecol 1993:81:261-4.
222. Scarabin PY. Plu-Burcau G, Bara L, Bonithon-Kopp C, Guize L. Samama MM. Haemostatic variables and menopausal status: influence oi hormone replacement therapy. Thromb Haemost 1993;70: 584-7.
223. Gains YG. Bauer KA, Barzegar S, ten Cale H. Sacks FM. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992:68:392-5
224. Meilahn EN. Kuller LH. Matth-ws KA, Kiss JE. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemicl 1992;2:445-55.
225. Fox J, George AJ, Newton JR, et al. Effect of transdenrmal oestradiol on the haemostatic balance of menopausal women. Maturitas 1993;18:55-64.
226. Lieberman EH. Gerhard MD. Uehata A, et al. Estrogen improves endothdium-defwndent, flow-mediated uasodilalion in postmenopausal women. Ann Intern Med 1994:121:936-41
227. Hillard TC. Bourne TH, Wriilehead MI. Crayford TB, Collins WP, Campbell S. Differential effects of transdermal estradiol and sequential progestogens on Impedance to flow within the uterine arteries of postmenopausal women Fertil Steril 1993;60:590-2.
228. Prelevte GM. Beljic T. The effect of oestrogen ind progesto-gtn replaceront thrrapy an tyiloflc flow velocity in healthy postmeno pausal women. Maturitas 1994;20:37-44.
229. Lindheim SR, Prcucr SC Ditkoff EC. Vitod MA. Stancnyk KZ Lobo RA. A possible bimodal effecl ol etrogen on insulin sensitivty in postmenopausal women and the attenuating effect of added progeson Fartil Strell 1993;60:664-7.
230. Lindhtim SR, Dnffy DM, Kojima T, Vijod MA. Stanciyk FZ. Lobo RA. The route of administration Influences the effnct of estrugen on insulin spensitivty In postmenopausal women Fertil Steril 62 1176-80.
231. O'Sullivan AJ. Ho KK. A comparison of the effects of oral and trarnsdermal cstrogcn replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 1996;80:1783-8
232. Cagnacci A, Soldani R. Camera PL. Faolerii AM. Fiorelti P. Metts GB Effects of low doses of transdermal 17 heta-estradiol on carbohydrate metabolism in postmeriopausal womnen. J Clin Endo crinol Metab 1992;74:1396-400
233. Haarbo J. Marslew U. Gotfredwn A. Chrisliansen C. Postmenopauval hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism 1991:40.1323-6.
234. Aloia JF, Vaswani A. Russo L. Sheehan M, Piaster E The influence of menopause and hormonal replacement therapy on body cett mass and body fat mass Am J Obstel Cynecol 1995:172:896-900
235. Sitruk-Ware R Cardfouascular risk at the menopause: role of sexual steroids. Norm Res 1995;43:58-63
236. Buring JE Hennekens CH. Randomked trials of primary prevention of cardiovascular diseases in women, an investigator's view. Ann Epldemiol 1994;4:111-4.
237. Klein BE. Klein R, Ritter LI. is there evidence of an estrogen dfect on age-relaled tens opacities? The Beaver Dam Eye Study Arch Ophthalrnol 1994;112:85-91.
238. Calle EE, Mirarle-McMahill HL. Thun MJ, Heath CW. Estrogen replacement therapy and risk of fatal coton cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995;87:517-23.
239. Risch HA, Howe GR. Menopausal hormone use and colorectal cancer in Saskatchewan: a record linkage cohort study. Cancer Epiderrdol Btomarkers Prev 1995:4:21-8.
240. McLennan SC, MacLennan AH. Ryan P. Colorectal cancer and oestrogen replacement therapy. A meta-analysis of epidmiological studies. Med J Austral 1995;162:491-3.
241. Grady D. Gebreisadik T, Kerlikowske T. Ernster V, Petilli D. Hormone replacement therapy and endometrial cancer risk: a metaanarysfe. Obstel Gynecol 1995;85:304-13.
242. Sarnsioe G. The endometrial effects of estrogen and estrogen-progeslogen replacement therapy Int J Fertll Menopausal Stud 1994: 39:84-92
243. Woodruff JO, Pickar JH. Incidence of endometrial hyperplasia in postmenopainal women taking conjugated estrogcns (Premarin) with medroxyprogesterotw acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994;170:1213-23.
244. McGonigle KF, Karlan BY, Barbuto DA. Leuchter RS, Lagasse LD. Judd HL. Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy. Gynecol Oncol 1994;55:126-32.
245. Hulka BS. Links between tormon? replacement therapy and neoplasio. Fertll Steril 1994:62:168S-75S.
246. Coldttz GA, Hankinson SE. Hunter DJ. et al. The use of estrogens and progestins and their risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
247. Stanford JL. Weiss NS, Voigt LF, Daling JR. Habel LA, Rossing MA. Combined estrogen and progestin hornone replacement ther-aphy relntion to risk of breast conrer in middle agent women JAMA 1995;274:137-42
248. Media Scan Docs hormone replacement therapy increase the risk of breast caner in postmenopausal women Two recently published studies disagree Contracept Rep 1995,VI 12.
249. Hindle WH. The continuing controversy about breast cancer risk artd nstrogon replacement therapy Menopause Mariage 1995;4: 12-.1
250. Grimes DA Comments. Contracepl Reo 1995;VI:12-3.
251. Banetl-Connor E. Postmenopausal estrogen and the risk of breast cancer. Ann Epidemiol 1994;4:177-80
252. Armstrong BK. Estrogen therapy after the menopause: boom or bane? Med J Aust 1988;18:213-4.
253. Duponl WD. Page DL Menopausal estrogen replatement thcrapy and brpasl cancer. Arch Intern Mel 1991:151-67-72
254. Steinberg KK. Tlackor SB. Smith SJ, et al. A meto-dnalysis of the effect al estragen replacement therapy on the risk of briast cancer JAMA 1991;265:1985,90
255. Sillcro Arenas M, Delgado Rodriguez M. Rodigues-Cantera R. Bueno Cavanillas A, Galwez-Vargas R. Menopausal hormone replatemtnl therapy and bieast cancer: a meta-analysis. 1992;79:286-94.
256. Mills PK. Bceson WL. Phillips, RL. Andress M. Fraser CE. Prospective study of exogenous hormone use and breast cancer in Seventh-Dey Adventist Cancer 1989;64:591-7.
257. Bergkvist L. Adami HO. Persson I. Hoover R. Scliairer C. The risk of breast cancer after estrogen and eitrogen-progestin replace ment. N Engl J Med 1989;321:293-7.
258. Hunt K. Vessey M. McPherson K, Coleman M. Long-term surveillancf of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987;94:620-35.
259. Rrsch HA, Howe GR. Menopausal homione usage and breast cancer in Saskatchewan a record-linkage cohort study. Am J Eptdemiol 1994:139:670-83.
260. Schairer C, Byrne C Keyl PM, Brinton LA. Slurgeon SR. Hoover RN. Menopausal estrogen and esrrogcn-piogestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994;5:491-500.
261. Bergkvist L, Adami HO. Peresson I, Bergstrom R, Krusemo UB. Prognosis alter breast cancer diagnosis in women exposed to estrogen and estrogen-proaestogen replacement therrapy. Am J Epidemiol 1989;130:221-8.
262. Jones C. Ingram D, Mattes E. Hahnel R. The effect of hormone replacement therapy on prognostic indices in women with breast cancer. Med J Aust 1994;161:106-10.
263. Brinton LA. Schairer C Estrogen replacement therapy and breast cancer risk. Epidemtol Rev 1993:15:66-79.
264. Boston Collaborative Drug Surveillance Program. Surgically confirmed gallbladder disease, venous thromboembolism. and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med 1974:290:15-9.
265. Kaltar F. Weiss NS. Strite SA. Non-contraceptive estrogen use and the risk of gallstone disease in women. Am J Pub Health 1988; 78:564-6.
266. Holly EA, Cress RD. Ahn DK. Cutaneous melanoma in women: ovulatory life, menopause:, and use of exogenous estrogens. Cancer Epidemiol Biomarkcrs Prev 1994;3:661-8.
267. Lieberman D, Kopeinik G. Porath A, Lazer S. Heimer D Sob-clinical worsening of bronchial asthma during estrogen replacement therapy in asthmasttc post-menopausal women. Maturitas 1995; 21:153-7.
268. Rodriguez C. Calle EE, Coates RJ. Miracle-McMahill HL. Thun MJ. Heath CW. Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 1995;141:828-35.
269. Mishell DR. Comment. Focus Opin Obstet Gynecol 1995;1: 369-70.